|
Fig. 4 Spatial metabolomics screened out discriminatory metabolites modulated by wedelolactone (WEL) and demethylwedelolactone (DWEL) on non-alcoholic fatty liver disease (NAFLD). (A) The hematoxylin and eosin (H&E) stain image for model, WEL or DWEL, and normal groups. (B) Metabolite-driven whole-body segmentation analysis based on the matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) data. (C) Whole-body principal component analysis (PCA). (D) Whole-body probabilistic latent semantic analysis (PLSA). (E) Liver specific PLSA analysis. (F?W) MALDI-MS images and expression levels of altered metabolites in zebrafish whole-body section and liver region. ???P < 0.001. CT: control; GPP: glucose phosphate; CSS: cholesterol sulfate; lysoPE: lyso-phosphatidylethanolamine; PE: phosphatidylethanolamine; C26:0-OH-SFT: C26:0-OH sulfatide; PS: phosphatidylserine; LysoPC: lyso-phosphatidylcholine; FAs: fatty acids.